Published 2 years ago

Pfizer to buy migraine drugmaker Biohaven in $11.6 billion deal

Summary by Ground News

Pfizer will pay $148.50 cash for each share of Biohaven Pharmaceuticals that it does not already own. Nurtec, a drug that belongs to a new class of migraine medicines that target calcitonin gene-related peptide (CGRP) Pfizer will also get a stake in the company formed from Biohaven's other assets.

0 Articles

All

Left

Center

Right

Times of India

Pfizer to acquire Biohaven by early 2023 for $11.6 billion

Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. announced that both the companies have entered into an agreement wherein Pfizer will acquire Biohaven. Biohaven makes the NURTEC® ODT, used for migraine therapy in adults.

2 years ago·India

Read Full Article

Reuters

Pfizer to buy migraine drugmaker Biohaven in $11.6 billion deal

Pfizer Inc said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding Company Ltd for about $11.6 billion in cash, as the drugmaker seeks to beef up its portfolio ahead of patent losses for some cancer drugs. Through the deal, Pfizer will gain access to Biohaven's approved drug Rimegepant that belong to a class of migraine drugs known as calcitonin gene-related

2 years ago·United Kingdom

Read Full Article

Associated Press News

Pfizer to spend $11.6B on migraine treatment maker Biohaven

Pfizer is starting to put its COVID-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area. The New York vaccine and cancer drug

2 years ago·United States

Read Full Article

abc News

Pfizer to spend $11.6B on migraine treatment maker Biohaven

Pfizer is starting to put its COVID-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area

2 years ago·United States

Read Full Article

CNBC

Cash-rich Pfizer to pay $11.6 billion for Biohaven in biggest deal since 2016

Pfizer said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding for about $11.6 billion in cash.

2 years ago·United States

Read Full Article

RTÉ

Pfizer to buy Biohaven Pharmaceutical for $11.6 billion

Pfizer said it will buy migraine drug maker Biohaven Pharmaceutical Holding Company for about $11.6 billion in cash, as the drugmaker seeks to beef up its portfolio ahead of patent losses for some cancer drugs.

2 years ago·Ireland

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.